The recent verdict in a Risperdal-related case may have tipped the ongoing mass-tort litigation in the plaintiffs’ favor, but attorneys are not expecting a global settlement any time soon.

A Philadelphia jury Monday awarded plaintiff Nicholas Murray $1.75 million on claims that the antipsychotic drug Risperdal caused gynecomastia, a condition in which boys grow excessive breast tissue. Murray, who has Asperger’s syndrome, had been prescribed the drug for his attention deficit hyperactivity disorder.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]